{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T15:57:56Z","timestamp":1717171076899},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1097\/inf.0b013e3182959f34","type":"journal-article","created":{"date-parts":[[2013,8,14]],"date-time":"2013-08-14T17:49:13Z","timestamp":1376502553000},"page":"990-997","source":"Crossref","is-referenced-by-count":4,"title":["Long-term Immune Responses to Pneumococcal Conjugate Vaccines in Children Previously Vaccinated With 7-valent Pneumococcal Conjugate Vaccine"],"prefix":"10.1097","volume":"32","author":[{"given":"Nicola P.","family":"Klein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathy","family":"Ensor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Jouve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Northington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Moscariello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul C.","family":"McGovern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-23-20210202","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00006454-200003000-00003","article-title":"Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group.","volume":"19","author":"Black","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"R2-23-20210202","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1097\/00006454-200209000-00005","article-title":"Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia.","volume":"21","author":"Black","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"R3-23-20210202","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM200102083440602","article-title":"Finnish Otitis Media Study Group. Efficacy of a pneumococcal conjugate vaccine against acute otitis media.","volume":"344","author":"Eskola","year":"2001","journal-title":"N Engl J Med"},{"key":"R4-23-20210202","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/01.inf.0000129685.04847.94","article-title":"Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente.","volume":"23","author":"Black","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"R6-23-20210202","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1086\/648593","article-title":"Active Bacterial Core SurveillanceEmerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine.","volume":"201","author":"Pilishvili","year":"2010","journal-title":"J Infect Dis"},{"key":"R7-23-20210202","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.vaccine.2009.12.054","article-title":"Indirect effect of conjugate pneumococcal vaccination in a 21 dose schedule.","volume":"28","author":"Vestrheim","year":"2010","journal-title":"Vaccine"},{"key":"R8-23-20210202","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/INF.0b013e31803df9ca","article-title":"Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine.","volume":"26","author":"Pelton","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"R9-23-20210202","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1016\/j.vaccine.2010.01.017","article-title":"Early effectiveness of heptavalent conjugate pneumococcal vaccination on invasive pneumococcal disease after the introduction in the Danish Childhood Immunization Programme.","volume":"28","author":"Harboe","year":"2010","journal-title":"Vaccine"},{"key":"R10-23-20210202","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa022823","article-title":"Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.","volume":"348","author":"Whitney","year":"2003","journal-title":"N Engl J Med"},{"key":"R12-23-20210202","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa0800836","article-title":"Effect of pneumococcal conjugate vaccine on pneumococcal meningitis.","volume":"360","author":"Hsu","year":"2009","journal-title":"N Engl J Med"},{"key":"R13-23-20210202","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMoa051642","article-title":"Active Bacterial Core Surveillance of the Emerging Infections Program Network. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae.","volume":"354","author":"Kyaw","year":"2006","journal-title":"N Engl J Med"},{"key":"R14-23-20210202","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1128\/JCM.44.3.999-1017.2006","article-title":"Active Bacterial Core Surveillance Team. Pre- and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002.","volume":"44","author":"Beall","year":"2006","journal-title":"J Clin Microbiol"},{"key":"R15-23-20210202","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1016\/j.vaccine.2007.01.119","article-title":"Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies.","volume":"25","author":"Siber","year":"2007","journal-title":"Vaccine"},{"key":"R16-23-20210202","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1128\/CDLI.10.4.514-519.2003","article-title":"Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides.","volume":"10","author":"Wernette","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"R17-23-20210202","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1128\/CDLI.4.4.415-422.1997","article-title":"Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells.","volume":"4","author":"Romero-Steiner","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"R18-23-20210202","doi-asserted-by":"crossref","first-page":"7207","DOI":"10.1016\/j.vaccine.2011.06.056","article-title":"The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A.","volume":"29","author":"Cooper","year":"2011","journal-title":"Vaccine"},{"key":"R20-23-20210202","first-page":"378","article-title":"Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults.","volume":"66","author":"Hak","year":"2008","journal-title":"Neth J Med"},{"key":"R21-23-20210202","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1097\/INF.0b013e3182372c6a","article-title":"3011 Study Group. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously immunized with 7-valent pneumococcal conjugate vaccine.","volume":"30","author":"Frenck","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R22-23-20210202","doi-asserted-by":"crossref","first-page":"5979","DOI":"10.1128\/IAI.67.11.5979-5984.1999","article-title":"Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination.","volume":"67","author":"Rubins","year":"1999","journal-title":"Infect Immun"},{"key":"R23-23-20210202","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1128\/CVI.00176-12","article-title":"Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults.","volume":"19","author":"Frenck","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"R24-23-20210202","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1086\/599824","article-title":"Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age.","volume":"49","author":"Miernyk","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R25-23-20210202","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1086\/597388","article-title":"Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years after vaccination.","volume":"199","author":"Madhi","year":"2009","journal-title":"J Infect Dis"},{"key":"R27-23-20210202","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1016\/j.vaccine.2010.02.087","article-title":"Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial.","volume":"28","author":"Russell","year":"2010","journal-title":"Vaccine"},{"key":"R28-23-20210202","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/jama.281.3.243","article-title":"Safety of revaccination with pneumococcal polysaccharide vaccine.","volume":"281","author":"Jackson","year":"1999","journal-title":"JAMA"},{"key":"R29-23-20210202","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0264-410X(03)00521-8","article-title":"Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia.","volume":"22","author":"Torling","year":"2003","journal-title":"Vaccine"},{"key":"R30-23-20210202","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1086\/591629","article-title":"Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia.","volume":"198","author":"Musher","year":"2008","journal-title":"J Infect Dis"},{"key":"R31-23-20210202","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1086\/529142","article-title":"Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory.","volume":"46","author":"de Roux","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R33-23-20210202","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1128\/CVI.00370-10","article-title":"Multilaboratory comparison of Streptococcus pneumoniae opsonophagocytic killing assays and their level of agreement for the determination of functional antibody activity in human reference sera.","volume":"18","author":"Rose","year":"2011","journal-title":"Clin Vaccine Immunol"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0b013e3182959f34","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:11:04Z","timestamp":1620954664000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201309000-00023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0b013e3182959f34","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}